Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD13 nanoCAR circular RNA
- Development stage
- Preclinical
- Lead developer
- Citil Pharma
- Modality
- Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CD13 nanoCAR circular RNA is an experimental in situ CAR T-cell therapy being developed by Citil Pharma for the treatment of Acute Myeloid Leukemia (AML). The therapeutic consists of circular RNA (circRNA) encoding a CD13-directed chimeric antigen receptor (CAR), encapsulated within lipid nanoparticles (LNPs) that are surface-functionalized with CD8-specific nanobodies. This delivery system specifically targets CD8+ T cells in vivo, where the circRNA is translated to transiently express the CD13 CAR. These engineered T cells then recognize and eliminate CD13-positive leukemia cells. By generating CAR T cells directly within the patient's body, this approach aims to overcome the logistical and manufacturing challenges associated with traditional ex vivo CAR T-cell therapies.
- Other names
- CD13 nanoCARCD-13 nanoCARCD 13 nanoCARCD8 Nanobody-Targeted LNP-delivered circular RNACD-8 Nanobody-Targeted LNP-delivered circular RNACD 8 Nanobody-Targeted LNP-delivered circular RNA
02
Targets
CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on CD13 nanoCAR circular RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD13 nanoCAR circular RNA.